Proffitt RT, Tran JV, Reynolds CP. A fluorescence digital image microscopy system for quantitating relative cell numbers in tissue culture plates. Cytometry 24:204-213. 1996
Krejsa J, Frgala F, Alfaro P, Reynolds CP. DIMSCAN 3.0, A New Generation of Fluorescence Digital Image Microscopy System for Measuring Cytotoxicity in Microplates. 2002 AACR Annual Meeting (poster). 2002
Ondrej Kalous, Julie Watanabe, Kun Jung Lee, A. Linn Murphree, C. Patrick Reynolds. Use Of A Novel Microplate Fluorescence Cytotoxicity Assay (Dimscan-384) To Evaluate Combinations Of Cytotoxic Agents In A Panel Of Retinoblastoma Cell Lines. 2003 AACR Annual Meeting. 2003
Ondrej Kalous, Jiri Krejsa, Tomas Frgala, C. Patrick Reynolds. The DIMSCAN cytotoxicity assay, unlike the MTT assay, identifies syngergistic combinations of anticancer agents.. 2004 AACR Annual Meeting. 2004
Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., and Reynolds, C. P.. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.. Methods Mol.Med., 110: 139-153. 2005
Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.. Mol Cancer Ther, 6(3):886-97. 2007
ABSTRCT FOR DIMSCAN
DIMSCAN is a semi-automatic digital image microscopy system for quantitating relative cell numbers in tissue culture plates. Cytotoxicity assays measured by DIMSCAN using fluorescein diacetate (FDA), a dye accumulating selectively in viable cells, can achieve a 4 log dynamic range at 4 to 7 days and correlate with colony forming assays. The system consists of an inverted fluorescence microscope, stepper motor scanning stage, the stage controller, CCD camera and a microcomputer running the main application, which controls stage movement and processes CCD camera images. Relative numbers of viable cells are determined by evaluating FDA fluorescence intensity, with background fluorescence eliminated by digital thresholding and a quenching of florescence in non-viable cells with the vital stain Eosin Y. The current system uses Olympus IX50 inverted florescence microscope, a Prior motorized stage, a Qimaging Microimager II camera, and a Pentium III computer running Windows 2000. Rectangular plates can be employed with number of wells ranging from 6 to 96 wells per plate. Average scan time for a 96 well plate is 6 minutes.
apers on DIMSCAN development
Authors
Paper name
Published in
Year
Proffitt RT, Tran JV, Reynolds CP
A fluorescence digital image microscopy system for quantitating relative cell numbers in tissue culture plates
Cytometry 24:204-213
1996
Krejsa J, Frgala F, Alfaro P, Reynolds CP
DIMSCAN 3.0, A New Generation of Fluorescence Digital Image Microscopy System for Measuring Cytotoxicity in Microplates
2002 AACR Annual Meeting (poster)
2002
Ondrej Kalous, Julie Watanabe, Kun Jung Lee, A. Linn Murphree, C. Patrick Reynolds
Use Of A Novel Microplate Fluorescence Cytotoxicity Assay (Dimscan-384) To Evaluate Combinations Of Cytotoxic Agents In A Panel Of Retinoblastoma Cell Lines
2003 AACR Annual Meeting
2003
Ondrej Kalous, Jiri Krejsa, Tomas Frgala, C. Patrick Reynolds
The DIMSCAN cytotoxicity assay, unlike the MTT assay, identifies syngergistic combinations of anticancer agents.
2004 AACR Annual Meeting
2004
Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., and Reynolds, C. P.
DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.
Methods Mol.Med., 110: 139-153
2005
Frgala T, Kalous O, Proffitt RT, Reynolds CP
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.
Mol Cancer Ther, 6(3):886-97
2007
[ Back to Top ]
Papers using DIMSCAN:
Authors
Paper name
Published in
Year
Reynolds CP, Schindler P, Jones D, Gentile J, Proffitt R, Einhorn P
Comparison of 13-cis- retinoic acid to trans-retinoic acid using human neuroblastoma cell lines
Advances in Neuroblastoma Research 4, Evans A, Biedler JL, Brodeur G, D'Angio GJ, Nakagawara A (eds.), New York: John Wiley & Sons, 237-244
1994
Keshelava N, Seeger RC, Reynolds CP
Drug resistance phenotype of neuroblastoma cell lines established at diagnosis and at relapse after induction chemotherapy or bone marrow transplantation
European J Cancer33:2002-2006
1997
Anderson CP, Tsai JM, Chan WW, Liu RM, Forman HJ, Reynolds CP
Buthionine sulfoximine (BSO) is cytotoxic via apoptosis and synergistically enhances the activity of melphalan (L-PAM) in human neuroblastoma cell lines
European J Cancer 33:2016-2019
1997
Keshelava N, Seeger RC, Groshen S, Reynolds CP
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
Cancer Research 58:5396-5405
1998
Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds G P
Depletion of Glutathione (GSH) by buthionine sulfoximine (BSO) is cytotoxic for human neuroblastoma cell lines via apoptosis
Neutrophils are cytotoxic and growth inhibiting for neuroblastoma cells with anti-GD2 antibody but without cytotoxicity can be growth stimulating
Clinical Immunol Immunother 48:603-612
2000
Maurer BJ, Cabot MC, Reynolds CP
Synergism of N-(4-hydroxyphenyl)retinamide cytotoxicity by modulators of ceramide metabolism in solid tumor cell lines
J Natl Cancer Inst 92:1897-1908
2000
Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ
Retinoic-acid resistant neuroblastoma cell lines show altered myc regulation and high sensitivity to fenretinide
Medical Pediatric Oncology 35:597-602
2000
Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche CJ, Reynolds CP
Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines
Cancer Research 61:6185-6193
2001
Anderson CP, Seeger RC, Satake N, Meek WE, Keshelava N, Bailey HH, Monforte-Munoz HL, Reynolds CP
Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line
J Pediat Hematol Oncol 23:500-505
2001
Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC
Enhanced expression and activation of Mac-1(CD11b/CD18) by an anti-GD2/GM-CSF fusion protein increases neutrophil antibody dependent cellular cytotoxicity
Blood 99:4166-4173
2002
O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes
Leukemia 16:902-910
2002
Anderson C, Reynolds CP
Cytotoxicity of buthionine sulfoximine (BSO) and melphalan/BSO in combination for neuroblastoma cell lines derived after myeloablative therapy
Bone Marrow Transplantation 30:135-140
2002
Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, and Malcolm A. Smith
Testing of New Agents in Childhood Cancer Preclinical Models : Meeting Summary
Clinical Cancer Research 8:3646-3657
2002
Bo Yang, Nino Keshelava, Clarke P. Anderson, and C. Patrick Reynolds
Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine
Cancer Research 63:1520-1526
2003
Nino Keshelava, Denice Tsao-Wei, and C. Patrick Reynolds
Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p531
Clinical Cancer Research 9:3492-3502
2003
Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.
In vitro testing of chemosensitivity in physiological hypoxia.
Methods Mol.Med., 110: 87-100
2005
Reynolds, C. P. and Maurer, B. J.
Evaluating response to antineoplastic drug combinations in tissue culture models.
Methods Mol.Med., 110: 173-183
2005
Yang, B. and Reynolds, C. P.
Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
Clin.Cancer Res., 11: 2774-2780
2005
Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Tony Ng T, Reynolds CP, Triche TJ, Sorensen PHB
E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.
Cancer Research, 67: 3094-3105
2007
Houghton PJ, Morton CL, Tucker C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Wu J, Smith MA
Stage 1 testing of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program.
Pediatric Blood & Cancer, (In Press).
2007
Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP
Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents.
J National Cancer Institute, 99:1107-19
2007
Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA
Initial testing (Stage 1) of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program.
Pediatric Blood & Cancer., (In Press)
2007
Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Blood, 110:205-2066
2007
Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB
Initial testing (Stage 1) of cisplatin by the Pediatric Preclinical Testing Program.
Pediatric Blood & Cancer, (In Press)
2007
Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA
Initial testing of dasatinib by the Pediatric Preclinical Testing Program.
Pediatric Blood & Cancer, (In Press)
2007
Reynolds CP, Kang MH, Keshelava N, Mauer BJ
Assessing combinations of cytotoxic agents using leukemia cell lines.
Current Drug Targets, 8:765-771
2007
[ Back to Top ]
Clinical Trials Enabled by DIMSCAN Testing:
Authors
Paper name
Published in
Year
Villablanca JG, Avramis V, Khan A, Matthay KK, Ram say NKC, Seeger RC, Reynolds CP
Phase I trial of 13-cis-retinoic acid (cRA) in neuroblastoma patients following bone marrow transplantation (BMT)
J Clinical Oncology13:894-901
1995
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shamada H, Black CG, Brodeur GM, Gerbing R, Reynolds CP
Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
New Eng J Med 341:1165-1173
1999
Villablanca JG, Ames MM, Reid JM, Bagniewski P, Krail M, Reynolds CP
Phase I trial of oral [N- (-4-hydroxyphenyl) retinamide] (4-HPR) in children with resistant/recurrent solid tumors: A Children's Cancer Group Study (CCG 09709)
Proc Amer Soc Clin Oncol21:398a
J Clinical Oncology24:3423-3430
2002
2006
Anderson CP, Robert Seeger RC, Bailey H, Reynolds CP
Pilot of buthionine sulfoximine (BSO) combined with non-myeloablative melphalan (L-PAM) against refractory neuroblastoma (NB)
Proc Amer Soc Clin Oncol21 :298a
2002
New Approaches to Neuroblastoma Therapy
N2002-01: A Phase I Study of High-Dose Pyrazoloacridine (PZA) (NSC 366140) Supported with Autologous Hematopoietic Stem Cell Rescue in Children with Recurrent or Resistant Neuroblastoma.
Closed
Children's Oncology Group
ANBL0321: A Phase II Study of Fenretinide in Children with Recurrent/Resistant High Risk Neuroblastoma.
Ongoing
New Approaches to Neuroblastoma Therapy
N99-02: A Phase I trial of BSO + L-PAM and Stem Cell Support.
Ongoing
Norris Cancer Center
A Phase II trial of Fenretinide in Recurrent Ovarian Cancer.
Proc Amer Soc Clin Oncol23:461
Proc Amer Soc Clin Oncol25: Abst 5555
2004
2007
California Cancer Consortium
A Phase II trial of Fenretinide in Prostate Cancer.
Ongoing
California Cancer Consortium
A Phase I trial of Intravenous Fenretinide in Hematological Malignancies.
Ongoing
California Cancer Consortium
A phase I trial of intravenous fenretinide in solid tumors
Ongoing
California Cancer Consortium
A phase II trial of fenretinide in asymptomatic rising PSA prostate cancer
Completed
New Approaches to Neuroblastoma Therapy
N2004-04: A Phase I Study of Fenretinide Lym-X-SorbTM (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68,254)
Ongoing
Therapeutic Advances in Childhood Leukemia
TACL 2005-001: A phase I/II trial of ABT-751 combined with dexamethasone, PEG-asparaginase, and doxorubicin in relapsed acute lymphoblastic leukemia (ALL)
Ongoing
Therapeutic Advances in Childhood Leukemia
TACL 2005-003: Bortezomib with chemotherapy for relapsed childhood ALL.
Ongoing
Therapeutic Advances in Childhood Leukemia
TACL 2006-001: IV Fenretinide in Relapsed ALL, AML or NHL.
